Agios Pharmaceuticals

<UNKNOWN> · 2 known investors

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease. The company's approach is grounded in cellular metabolism research and involves close collaboration with patients and clinical partners.

BiotechHealthtechMedical Devices